Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, today announced a publication in Nature Communications demonstrating that the histone lysine methyltransferase enzyme Suv39h1 plays...
Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, announced the kick-off of their participation in the prestigious Hospital-University Research in Health (RHU) program. Designed...
Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, announced a publication in Cell Reports that demonstrates peptides derived from transposable elements (TEs) – mobile...
